Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
SRRK · against 228 other Healthcare companies of similar size
Ranked #177 of 229 · scores higher than 2% of peers
Bars: peers in each 10-point band of the valuation score53 peers with a valuation score of 0–9, including SRRK · Click a bar to see the companies
Mainly because of its EBITDA yield, earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
| Metric | SRRK | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 226 reported | -7.6% | 2.4% | 9% | 30% | |
| EBITDA yieldHigher is better · 226 reported | -8.0% | 4.5% | 6% | 50% | |
| Free cash flow yieldHigher is better · 129 reported | -5.5% | 0.8% | 15% | 20% | |
| Book yieldHigher is better · 227 reported | 4.7% | 24.5% | 8% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.3B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 1 | 37.3B HKD (≈$4.8B) | 99 | 90 | |
| 4 | 21.1B HKD (≈$2.7B) | 98 | 67 | |
| 4 | 428.3B JPY (≈$2.9B) | 98 | 59 | |
| 177 | 3.7B USD | 8 | 24 | |
| 177 | 7.8B USD | 8 | 30 | |
| 177 | 3.8B USD | 8 | 48 | |
| 177 | 6.0B USD | 8 | 32 | |
| 177 | 5.4B USD | 8 | 24 | |
| 177 | 3.4B USD | 8 | 48 | |
| 177 | 3.9B USD | 8 | 52 | |
| 177 | 9.3B USD | 8 | 29 | |
| 177 | 8.5B USD | 8 | 28 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score